O’Connor O. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in heavily pretreated patients with hematological malignancies. Hematol Meeting Rep [Internet]. 2009 Jun. 3 [cited 2024 Nov. 23];1(8). Available from: https://www.pagepress.org/journals/hmr/article/view/297